DN 1406131
Alternative Names: DN131; DN1406131Latest Information Update: 28 Aug 2025
At a glance
- Originator Shanghai De Novo Pharmatech
- Developer Jiangxi Qingfeng Pharmaceutical; Shanghai De Novo Pharmatech
- Class Antineoplastics
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in Solid-tumours(In volunteers) in China (PO)
- 28 Jul 2022 DN 1406131 is still in phase I trials for Solid tumours in China (Shanghai De Novo Pharmatech pipeline, July 2022)
- 28 Jul 2022 Phase-I clinical trials in Solid tumours (In volunteers) in China (PO) (Shanghai De Novo Pharmatech pipeline, July 2022)